Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
Main Authors: | Redmond, William L, Linch, Stefanie N, Kasiewicz, Melissa J |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991178/ |
Similar Items
-
Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer
by: Linch, Stefanie N, et al.
Published: (2013) -
Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts
by: Linch, Stefanie N, et al.
Published: (2014) -
Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice
by: Linch, Stefanie, et al.
Published: (2015) -
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
by: Linch, Stefanie N., et al.
Published: (2015) -
Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
by: Friedman, David J, et al.
Published: (2014)